The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia

Hemoglobin. 2019 Jul-Sep;43(4-5):264-272. doi: 10.1080/03630269.2019.1692863. Epub 2019 Nov 25.

Abstract

A retrospective evaluation of growth in 112 patients (68 males, 44 females) with Hb E (HBB: c.79G>A)/β-thalassemia (β-thal), classified as 88 transfusion-dependent thalassemia (TDT) and 24 non transfusion-dependent thalassemia (NTDT), is reported. Patients with TDT have received regular transfusions of red blood cells (RBCs) 15 mL/kg every 4 weeks to maintain pre transfusion hemoglobin (Hb) levels of at least 9.0 g/dL and were categorized according to age at initiation of regular RBC transfusion as subgroup 1, <4 years; subgroup 2, 4-10 years, and subgroup 3, >10 years. Iron chelation was initiated at the mean age of 7 years. The results revealed that patients in subgroups 1 and 2, receiving RBC transfusions at a young age (2.9 and 6.9 years, respectively), had normal prepubertal growth at enrollment and last follow-up. Patients in subgroup 3, with the lowest initial height Z-score of -2.10, were able to achieve comparable final adult height as those in subgroups 1 and 2. The mean final height of 21 males and 13 females with TDT at the ages of 18.9 and 18.7 years was 168.1 and 157.7 cm, respectively, which did not significantly differ from their midparental height and those with NTDT. Early initiation of optimal transfusion and iron chelation promoted normal prepubertal growth. However, delayed initiation of transfusion at age 12 years impaired prepubertal growth but they could achieve normal final adult height.

Keywords: Final height; Hb E/β-thalassemia (Hb E/β-thal); growth.

MeSH terms

  • Adolescent
  • Blood Transfusion*
  • Body Height*
  • Chelation Therapy
  • Child
  • Child, Preschool
  • Female
  • Hemoglobin E / adverse effects*
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Male
  • Retrospective Studies
  • beta-Thalassemia / physiopathology
  • beta-Thalassemia / therapy*

Substances

  • Iron Chelating Agents
  • Hemoglobin E